BioXcel Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/S Ratio8.1962.581605.17
P/B Ratio-0.20-1.537.842.575.45
Price/Tangible Book7.842.575.45
Enterprise Value Ratios
EV/Revenue36.6969.821233.33
Profitability & Returns
Return on Equity (ROE)-17.67%-1.11%-0.50%-0.70%
Return on Assets (ROA)-0.72%-0.75%-0.45%-0.29%-0.40%
Return on Capital Employed (ROCE)-4.02%-3.61%-0.92%-0.48%-0.40%
Leverage & Solvency Ratios
Debt/Equity-1.11-1.791.220.010.01
Liquidity Ratios
Current Ratio1.682.656.1714.2118.33
Quick Ratio1.352.405.9013.9818.00
Efficiency Ratios
Asset Turnover0.040.010.00
Inventory Turnover1.600.63
Yield & Distribution Ratios
Earnings Yield-3.21%-2.07%-0.28%-0.19%-0.07%
FCF Yield-3.88%-1.80%-0.23%-0.15%-0.06%
Buyback Yield-0.39%-0.04%-0.06%-0.22%-0.33%